Significance of trans-hepatic arterial chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombus

Oncology Reports

Volumn 20, Issue 2, 2008, Pages 353-357

  Akiyama, Motohisa ^a   Miyaaki, Hisamitsu ^a   Miuma, Satoshi ^a   Shibata, Hidetaka ^a   Fujimoto, Masumi ^a   Takeshita, Shigeyuki ^a   Ozawa, Eisuki ^a   Ichikaw, Tatsuki ^a   Nakao, Kazuhiko ^a   Eguchi, Katsumi ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

Hepatocellular carcinoma; Liver cirrhosis; Portal vein tumor thrombus; Trans arterial chemotherapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; BILIRUBIN; CISPLATIN; FLUOROURACIL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTERY CATHETER; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG CONTRAINDICATION; DRUG EFFICACY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROGNOSIS; PROTHROMBIN TIME; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTE COUNT; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR THROMBUS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CISPLATIN; FEMALE; FLUOROURACIL; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MALE; MIDDLE AGED; PORTAL VEIN; PROGNOSIS; SURVIVAL RATE; VENOUS THROMBOSIS;

EID: 48749119883     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or_00000014     Document Type: Article

References (36)

1. Farmer DG, Rosove MH, Shaked A and Busuttil RW: Current treatment modalities for hepatocellular carcinoma. Ann Surg 219: 236-247, 1994.
2. Shinagawa T, Ohto M, Kimura K, et al: Diagnosis and clinical features of small hepatocellular carcinoma with emphasis on the utility of real-time ultrasonography. A study in 51 patients. Gastroenterology 86: 495-502, 1984.
3. Takayasu K, Moriyama N, Muramatsu Y, et al: Hepatic arterial embolization for hepatocellular carcinoma. Comparison of CT scans and resected specimens. Radiology 150: 661-665, 1984.
4. Yoshida H, Itai Y, Ohtomo K, Kokubo T, Minami M and Yashiro N: Small hepatocellular carcinoma and cavernous hemangioma: differentiation with dynamic FLASH MR imaging with Gd-DTPA. Radiology 171: 339-342, 1989.
5. Chen MF and Jeng LB: Partial hepatic resection for hepatocellular carcinoma. J Gastroenterol Hepatol 12: S329-S334, 1997.
6. Omata M, Tateishi R, Yoshida H and Shiina S: Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: Ethanol injection therapy and radiofrequency ablation. Gastroenterology 127: S159-S166, 2004.
7. Shiina S, Teratani T, Obi S, Hamamura K, Koike Y and Omata M: Nonsurgical treatment of hepatocellular carcinoma: from percutaneous ethanol injection therapy and percutaneous microwave coagulation therapy to radiofrequency ablation. Oncology 62 (Suppl 1): 64-68, 2002.
8. Xiao EH, Hu GD, Li JQ and Huang JF: Transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma. Zhonghua Zhong Liu Za Zhi 27: 478-482, 2005.
9. Tamura S, Kato T, Berho M, et al: Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation. Arch Surg 136: 25-31, 2001.
10. Stuart KE, Anand AJ and Jenkins RL: Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer 77: 2217-2222, 1996.
11. Minagawa M and Makuuchi M: Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. World J Gastroenterol 12: 7561-7567, 2006.
12. Cady B: Natural history of primary and secondary tumors of the liver (Review). Semin Oncol 10: 127-134, 1983.
13. Yamanaka N, Okamoto E, Toyosaka A, et al: Prognostic factors after hepatectomy for hepatocellular carcinomas. A univariate and multivariate analysis. Cancer 65: 1104-1110, 1990.
14. Fuster J, Garcia-Valdecasas JC, Grande L, et al: Hepatocellular carcinoma and cirrhosis. Results of surgical treatment in a European series. Ann Surg 223: 297-302, 1996.
15. Hsu HC, Wu TT, Wu MZ, et al: Tumor invasiveness and prognosis in resected hepatocellular carcinoma. Clinical and pathogenetic implications. Cancer 61: 2095-2099, 1988.
16. Llovet JM, Bustamante J, Castells A, et al: Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 29: 62-67, 1999.
17. Villa E, Moles A, Ferretti I, et al: Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival. Hepatology 32: 233-238, 2000.
18. Asahara T, Itamoto T, Katayama K, et al: Hepatic resection with tumor thrombectomy for hepatocellular carcinoma with tumor thrombi in the major vasculatures. Hepatogastroenterology 46: 1862-1869, 1999.
19. Tanaka A, Morimoto T, Ozaki N, et al: Extension of surgical indication for advanced hepatocellular carcinoma: is it possible to prolong life span or improve quality of life? Hepatogastroenterology 43: 1172-1181, 1996.
20. Yamaoka Y, Kumada K, Ino K, et al: Liver resection for hepatocellular carcinoma (HCC) with direct removal of tumor thrombi in the main portal vein. World J Surg 16: 1172-1177, 1992.
21. Furuse J, Iwasaki M, Yoshino M, et al: Hepatocellular carcinoma with portal vein tumor thrombus: embolization of arterioportal shunts. Radiology 204: 787-790, 1997.
22. Yen FS, Wu JC, Kuo BI, Chiang JH, Chen TZ and Lee SD: Transcatheter arterial embolization for hepatocellular carcinoma with portal vein thrombosis. J Gastroenterol Hepatol 10: 237-240, 1995.
23. Chen SC, Lian SL and Chang WY: The effect of external radiotherapy in treatment of portal vein invasion in hepatocellular carcinoma. Cancer Chemother Pharmacol 33 (Suppl 1): 124-127, 1994.
24. Sakon M, Nagano H, Dono K, et al: Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 94: 435-442, 2002.
25. Cheong JY, Lee KM, Cho SW, et al: Survival benefits of intraarterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. Hepatol Res 32: 127-133, 2005.
26. Yan P and Yan LN: Staging of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2: 491-495, 2003.
27. Huang YH, Chen CH, Chang TT, et al: Evaluation of predictive value of CLIP, Okuda, TNM and JIS staging systems for hepatocellular carcinoma patients undergoing surgery. J Gastroenterol Hepatol 20: 765-771, 2005.
28. Falkson G, Lipsitz S, Borden E, Simson I and Haller D: Hepatocellular carcinoma. An ECOG randomized phase II study of beta-interferon and menogaril. Am J Clin Oncol 18: 287-292, 1995.
29. Shen DW, Lu YG, Chin KV, Pastan I and Gottesman MM: Human hepatocellular carcinoma cell lines exhibit multidrug resistance unrelated to MRD1 gene expression. J Cell Sci 98: 317-322, 1991.
30. Okada S, Okazaki N, Nose H, Yoshimori M and Aoki K: Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Hepatology 16: 112-117, 1992.
31. Ando E, Yamashita F, Tanaka M and Tanikawa K: A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein. Cancer 79: 1890-1896, 1997.
32. Patt YZ, Yoffe B, Charnsangavej C, et al: Low serum alpha-fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5-FU and interferon-alpha-2b. Cancer 72: 2574-2582, 1993.
33. Ando E, Tanaka M, Yamashita F, et al: Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 95: 588-595, 2002.
34. Obi S, Yoshida H, Toune R, et al: Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 106: 1990-1997, 2006.
35. Raoul JL, Boucher E and Kerbrat P: Nonsurgical treatment of hepatocellular carcinoma. Bull Cancer 86: 537-543, 1999.
36. Abou-Alfa GK, Schwartz L, Ricci S, et al: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24: 4293-4300, 2006.